@article{826c54231e434c3c98fa6f43e83d0563,
title = "Randomized, controlled trial of transdermal clonidine for smoking cessation",
abstract = "OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and {Del Core}, Michael and Lucas, {B. Daniel}",
year = "1993",
doi = "10.1177/106002809302700901",
language = "English",
volume = "27",
pages = "1025--1028",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",
}